Skip to content

Prospective randomized controlled trial of laparoscopic D2 lymphadenetomy plus complete mesogastrium excision (D2+CME) vs. laparoscopic D2 lymphadenetomy for advanced gastric cancer

Prospective randomized controlled trial of laparoscopic D2 lymphadenetomy plus complete mesogastrium excision (D2+CME) vs. laparoscopic D2 lymphadenetomy for advanced gastric cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003754
Enrollment
Unknown
Registered
2013-10-29
Start date
2013-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

A:laparoscopic D2 lymphadenetomy
B:laparoscopic D2 lymphadenetomy plus complete mesogastrium excision (D2+CME)

Sponsors

Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College in Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Preoperative endoscopy and biopsy confirmed gastric adenocarcinoma; 2. potentially resectable disease by preoperative staging assessment, including UICC cTNM stage I-IIIa (cT1N0M0-cT3N1M0, except cT4N0M0); 3. Aged from 18 yrs to 75 yrs; no limitation to gender; BMI no more than 30 kg/m^2; WHO performance scale less than 2 score; 4. Informed consent obtained from patients or their appointed agent.

Exclusion criteria

Exclusion criteria: 1. Patients treated with neoadjuvant chemotherapy or radiation therapy; 2. Patients with history of upper abdominal surgery; 3. With other severe comorbidities and cannot tolerate laparoscopic surgery, such as severe heart and lung diseases, heart function below clinical stage 2, pulmonary infection, moderate to severe COPD, chronic bronchitis, severe diabetes and / or renal insufficiency, severe hepatitis and / or function below the rank of CHILD B grade, and severe malnutrition, etc; 4. Patients suffering from malignant diseases before the study or with other gastric malignant diseases, such as lymphoma and stromal tumors, etc.; 5. Pregnant woman and woman during lactation; 6. Patients with mental sickness; 7. The patient compliance is bad or the researcher expect there will not be good patient compliance.

Design outcomes

Primary

MeasureTime frame
3 and 5-year survival rate;Complications;blood loss during operation;Operation time;The number of lymph node dissection;Intestinal recovery exhaust time;Positive rate of cancer cells from intraperitoneal;

Countries

China

Contacts

Public ContactJianping Gong

Department of Gastrointestinal Surgery, Tongji Hospital, Wuhan, Hubei

jpgong@tjh.tjmu.edu.cn+86 13607189315

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026